Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for the treatment and prevention of addiction and related disorders. The company's mission is to provide hope and improved outcomes for individuals struggling with alcohol addiction through innovative scientific research and development. Adial Pharmaceuticals is headquartered in Glen Allen, Virginia.

The company's primary product candidate is AD04, a genetically targeted, serotonin-3 receptor antagonist. AD04 is being developed as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in patients with specific target genotypes, which are identified using the company's proprietary companion diagnostic genetic test. Adial Pharmaceuticals operates within the addiction treatment sector of the biopharmaceutical industry, addressing a market characterized by high unmet medical needs.

Cary J. Claiborne serves as the Chief Executive Officer. In recent developments, Adial Pharmaceuticals filed a new U.S. utility patent application for AD04, aiming to protect core assets through at least 2045. The company also submitted an application to the FDA Commissioner's National Priority Voucher Pilot Program for AD04's clinical development and successfully completed the manufacturing of a demonstration batch for AD04, enabling planned Phase 3 clinical and registration production. Additionally, Adial Pharmaceuticals signed an exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe, which anticipates potential royalties and milestones. The company regained full compliance with Nasdaq listing requirements in February 2026.